Crossmark

Can direct smear results that are routinely collected at health centre level be used for monitoring the impact of mass drug administration with praziquantel on schistosomiasis in Burundi? A preliminary assessment

Crossref DOI link: https://doi.org/10.1186/s13071-020-04076-4

Published Online: 2020-04-21

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bizimana, Paul

Polman, Katja

Ortu, Giuseppina

Krit, Meryam

Nsabiyumva, Frédéric

Nkeshimana, Audace

Bijabuka, Urlich

Nibakire, Marcelline

Van Geertruyden, Jean-Pierre
Funding

Funding for this research was provided by:

Schistosomiasis Control Initiative

VLIR-UOS
License Information

Text and Data Mining valid from 2020-04-21

Version of Record valid from 2020-04-21
More Information

Article History

Received: 24 December 2019

Accepted: 10 April 2020

First Online: 21 April 2020

Ethics approval and consent to participate

: The research protocol was reviewed and approved by the National Ethics Committee of Burundi in September 2013. Authorisation from the Ministry of Public Health for the study was provided in May 2014.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below